Tetra Bio-Pharma Initiates Additional Studies on Leading Drug Candidate ARDS-003

March 26, 2021 2:00 AM

Tetra Bio-Pharma and Targeted Pharmaceuticals enter into an agreement to further its collaboration and co-development activities to advance Antiviral Central Nervous System Program The addressable global market for central nervous system drugs is expected to grow to $163.05 billion in 2025 OTTAWA, ON / ACCESSWIRE / March 26, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a...

Read more

Medical Data Systems, Inc.: Using Machine Learning To Enhance Account Recovery For Over 500 Hospitals Despite Pandemic Restrictions

March 25, 2021 10:20 PM

VERO BEACH, FL / ACCESSWIRE / March 25, 2021 / Hospitals have battled enormous challenges during the 2020 pandemic. Behind the scenes of the pandemic response one company's specialized account recovery process has helped over 500 hospitals nationwide keep cash flow moving and patient's informed of the changes in healthcare. Saving many hospitals from having to cut jobs and turn away patients. Behind all this success...

Read more

Pieris Announces Amendment of Existing Immuno-oncology Multi-target Collaboration with Seagen, a Clinical Trial and Supply Agreement to Evaluate Cinrebafusp Alfa (PRS-343) in Combination with TUKYSA(R) (tucatinib) in Gastric Cancer, and Strategic Equity Investment by Seagen

March 25, 2021 8:00 AM

Seagen will supply Pieris with TUKYSA® to evaluate the drug in combination with cinrebafusp alfa (PRS-343) in gastric cancer Pieris' co-development option for one program from existing multi-target collaboration amended to US co-promotion option with increased royalties if exercised Seagen to purchase $13 million equity stake in Pieris common stock BOSTON, MA / ACCESSWIRE / March 25, 2021 / Pieris Pharmaceuticals, Inc....

Read more

Molecular Partners Nominates Dominik Höchli, M.D., for Election to Its Board of Directors

March 25, 2021 2:00 AM

Pharmaceutical industry expert with extensive knowledge of R&D and commercialization ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 25, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the nomination of Dominik Höchli, M.D., to the Company's Board of Directors proposed for...

Read more

Boston Red Sox to Partner with Applied UV to Install Airocide(R) Air Quality System in Fenway Park and Jet Blue Park

March 24, 2021 8:30 AM

MOUNT VERNON, NY / ACCESSWIRE / March 24, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that it has partnered with the Boston Red Sox to...

Read more

Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer

March 24, 2021 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / March 24, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the Company has officially opened its Phase I trial to evaluate Pritumumab (PTB), the...

Read more

Lexaria Technology Generates Positive Stability Testing for World-Class Ready-to-Drink CBD Beverages

March 24, 2021 7:00 AM

DehydraTECHTM CBD-Beverage Demonstrates 93.4% Potency One Year After Production Lexaria's Nanoemulsification Processing Technique Ensures Content Uniformity and Homogeneity of CBD Distribution Without Need for Physical Mixing KELOWNA, BC / ACCESSWIRE / March 24, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery...

Read more

CORRECTION: Wuhan Launches Medspresso CBD Infused Whole Bean Roasted Coffee

March 23, 2021 2:25 PM

This press release replaces the press release disseminated March 23rd, 2021 at 12:15 PM ET. The press release was missing the fifth paragraph. The corrected press release is below: CAPE TOWN, SA / ACCESSWIRE / March 23, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce...

Read more

Wuhan Launches Medspresso CBD Infused Whole Bean Roasted Coffee

March 23, 2021 12:15 PM

CAPE TOWN, SA / ACCESSWIRE / March 23, 2021 / WUHAN GENERAL GROUP, INC. (WUHN) ("Wuhan'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce today that the Company is launching the MedspressoTM CBD infused whole-bean roasted coffee line. The new line is offered in both whole-bean and ground coffee formats. The CBD infused whole-bean...

Read more

Stella Diagnostics to Present at the Benzinga Biotech Small Cap Conference

March 23, 2021 11:35 AM

SALT LAKE CITY, UT / ACCESSWIRE / March 23, 2021 / Stella Diagnostics, Inc. (OTC Markets:JMDP) ("Stella" or "The Company") announced today that the Company's Chief Executive Officer, Dr. Joe Abdo, will participate in the Benzinga Biotech Small Cap Conference to be held virtually March 24-25, 2021. Dr. Abdo will present a corporate update and participate in a live Q&A with registered attendees starting at 2:10 pm EDT...

Read more

RE-TRANSMISSION: GeneCentric Therapeutics Announces New US Patent Granted for Molecular Characterization of Non-Squamous Non-Small Cell Lung Cancer

March 23, 2021 9:30 AM

Patent Provides Framework for Further Development of Novel Lung Cancer Molecular Diagnostic Tests DURHAM, NC / ACCESSWIRE / March 23, 2021 / GeneCentric Therapeutics, a company making precision medicine more precise, announced today the granting of Patent No. 10,934,595 by the United States Patent and Trademark Office (USPTO), protecting another one of its novel RNA-based lung cancer gene signatures. This new patent provides further...

Read more

Afecta Pharmaceuticals Announces Grant of U.S. Patent

March 23, 2021 9:00 AM

IRVINE, CA / ACCESSWIRE / March 23, 2021 / Afecta Pharmaceuticals, a company focused on developing drugs that modulate key pathways that drive disease processes associated with immune disorders, neurological dysfunction and cancers, announced that the United States Patent and Trademark Office has granted a patent on March 9, 2021 for a class of novel compounds that inhibit the CCL5/RANTES pathway. The patent, U.S. Patent No. 10,940,132,...

Read more

Movano Inc. Prices $42.5 Million Public Offering of Common Stock

March 23, 2021 8:00 AM

PLEASANTON, CA / ACCESSWIRE / March 23, 2021 / Today, Movano Inc. (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health in order to prevent and better manage chronic diseases, announced the pricing of its initial public offering of 8,500,000 shares of its common stock at a public offering price of $5.00 per share. All of the shares are being offered by Movano Inc. In addition, Movano Inc....

Read more

Pieris Pharmaceuticals to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 30, 2021

March 23, 2021 8:00 AM

BOSTON, MA / ACCESSWIRE / March 23, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a full-year 2020 investor call on Tuesday, March 30, 2021 at 8:00 AM EDT to discuss financial results and provide a corporate update. To...

Read more

Lexaria to Present at the Benzinga Biotech Small Cap Conference on March 24, 2021 at 9:45 AM ET

March 23, 2021 7:00 AM

Lexaria recently announced progress on its hypertension R&D program, consisting of three human clinical and two animal studies, as well as two studies in its antiviral drug evaluation program KELOWNA, BC / ACCESSWIRE / March 23, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that CEO Chris Bunka is...

Read more

Bio Lab Naturals, Inc. a Delaware Corporation, (BLAB:OTC) Addresses a Yahoo Press Release Containing Information that was not Applicable to the Company

March 22, 2021 3:25 PM

DENVER, CO / ACCESSWIRE / March 22, 2021 / Bio Lab Naturals, Inc., a Delaware corporation, "BLAB" (OTCQB:BLAB) based in Denver, Colorado wishes to clear up any confusion as to a news release dated January 6, 2020, that appears on Yahoo Finance on the quote page for Bio Lab Naturals, Inc. ("BLAB" OTC). That news release related to a proposed transaction between Canavation, Inc. of Tampa, Florida, and Bio Lab Naturals, Inc. a...

Read more

Molecular Partners Announces Intention to Conduct a Registered Offering in the United States

March 22, 2021 12:40 PM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 22, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares ("ADSs"), in the United States and has confidentially submitted a draft...

Read more

Wuhan Announces Opening Cape Town Office

March 22, 2021 9:15 AM

CAPE TOWN, SA / ACCESSWIRE / March 22, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce today that the Company has signed a lease on a new office in Cape Town's trendy Woodstock area. The move will take place this week and will enable the company's divisions,...

Read more

Edesa Biotech Expands Rights to Anti-Inflammatory Technology

March 22, 2021 7:45 AM

TORONTO, ON / ACCESSWIRE / March 22, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that it has entered into a definitive license agreement under which the company, through a subsidiary, has acquired additional global rights to a non-steroidal anti-inflammatory technology that forms the basis of the company's EB01 and EB02 drug...

Read more

OMNICANNA/Thermic Appoints Mr. Hendrik Schutte as Research Director of Electrical Components, Sales & Development (DECS), Renewable Thermic Solid State Battery Power Units and Thermic Self-Generating Electrical Power Units, International Sales & Distribution

March 19, 2021 8:20 AM

NASHVILLE, TN / ACCESSWIRE / March 19, 2021 / Thermic Sciences International, former known as Omnicanna Health Solutions, Inc. aka ENDOCAN CORP. (WKN: A1W61J, ISIN: US29271J1097, OTC PINK:ENDO), is pleased to announce the appointment of Mr. Hendrik Schutte as Research Director of Electrical Components, Sales & Development (DECS), as TSi moves forward with its Thermic technology and the new Electroluminescent Litcoat initiatives as the...

Read more